{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:32:37Z","timestamp":1788449557874,"version":"build-2803163510"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer remains one of the most common and deadliest diseases worldwide. Among endocrine neoplasms, the incidence of thyroid malignancies has been rising in recent years. Papillary thyroid carcinoma (PTC), the most frequently observed histological subtype of thyroid cancer (THCA), typically yields favorable clinical outcomes for affected individuals. However, this has raised concerns about the overdiagnosis and underdetermination of the prognostic factors in PTC cases. As a result, researchers now advocate for patient stratification and tailored therapeutic approaches for PTC cases, with the goal of minimizing unnecessary surgical procedures and radioiodine treatments. These treatments can lead to clinical complications and impose avoidable physiological and psychological stress on patients. Multiple prognostic biomarkers have been identified for PTC, which play a critical role in predicting outcomes and informing treatment decisions. This review examines both established molecular tools and recent advancements in the determination of prognosis in in papillary thyroid carcinoma.<\/jats:p>","DOI":"10.3389\/fonc.2025.1598934","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:25:49Z","timestamp":1747805149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Application and recent advances in conventional biomarkers for the prognosis of papillary thyroid carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Muzi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cancan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A","article-title":"Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. u.s. and german thyroid cancer study group. an american college of surgeons commission on cancer patient care evaluation study","volume":"89","author":"Hundahl","year":"2015","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0021","article-title":"Thyroid cancer incidence patterns in the United States by histologic type, 1992\u20132006","volume":"21","author":"Aschebrook-Kilfoy","year":"2011","journal-title":"Thyroid."},{"key":"B4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/thy.2012.0329","article-title":"Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades","volume":"23","author":"Cho","year":"2013","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v136.9","article-title":"Thyroid cancer mortality and incidence: a global overview","volume":"136","author":"La Vecchia","year":"2015","journal-title":"Int J Cancer J Int Du Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.11.4373","article-title":"Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients","volume":"82","author":"Loh","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12957-016-0979-1","article-title":"Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis","volume":"14","author":"Liu","year":"2016","journal-title":"World J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2018052","article-title":"National epidemiologic survey of thyroid cancer (NEST) in korea","volume":"40","author":"Oh","year":"2018","journal-title":"Epidemiol Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/his.14700","article-title":"WHO 2022 landscape of papillary and chromophobe renal cell carcinoma","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.9.1203","article-title":"Surgical management of thyroid cancer","volume":"7","author":"Ramirez","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766","article-title":"Davies h, bignell gr, cox c et\u00a0al.mutations of the braf gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: b-raf is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","article-title":"Braf mutations and ret|[sol]|ptc rearrangements are alternative events in the etiopathogenesis of ptc","volume":"22","author":"Soares","year":"2003","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/thy.2008.0144","article-title":"Clinical and pathological features and the braf(v600e) mutation in patients with papillary thyroid carcinoma with and without concurrent hashimoto thyroiditis","volume":"19","author":"Kim","year":"2009","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030305","article-title":"Clinical implication of hot spot braf mutation, v599e, in papillary thyroid cancers","author":"Namba","year":"2003","journal-title":". J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000797","article-title":"BRAF mutations in thyroid cancer","volume":"34","author":"Scheffel","year":"2022","journal-title":"Current opinion in oncology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0063","article-title":"Braf and tert promoter mutations: clinical application in thyroid cancer","volume":"67","author":"Chung","year":"2020","journal-title":"Endocrine J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.507","article-title":"High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the ret\/ptc-ras-braf signaling pathway in papillary thyroid carcinoma1","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3314","article-title":"Conditional brafv600e expression induces dna synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid pccl3 cells","volume":"65","author":"Mitsutake","year":"2005","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent tert promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1230062","article-title":"Tert promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telo-merase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba","year":"2017","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic tert promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent tert promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocrine Related Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of braf mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani","year":"2012","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between nras and braf mutational status and melanoma-specific survival among patients with higher-risk primary melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1120-y","article-title":"Brafv600e mutation is a negative prognosticator in pediatric ganglioglioma","volume":"125","author":"Dahiya","year":"2013","journal-title":"Acta Neuropathologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1541","article-title":"Braf and nras locus specific variants have different outcomes on survival to colorectal cancer","volume":"23","author":"Summers","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"dju246","DOI":"10.1093\/jnci\/dju246","article-title":"Tert promoter mutation status as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Griewank","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v139.1","article-title":"Tertpromoter mutations in melanoma survival","volume":"139","author":"Nagore","year":"2016","journal-title":"Int J Cancer."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1784-x","article-title":"Coexistence of tert promoter and braf mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness","volume":"467","author":"Macerola","year":"2015","journal-title":"Virchows Archiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant tert by braf v600e\/map kinase pathway through fos\/gabp in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/328170a0","article-title":"A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases","volume":"328","author":"Fusco","year":"1987","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"Ret\/ptc rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocrine Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00054","article-title":"Ret\/ptc translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Cristina","year":"2012","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46382","article-title":"Small-molecule mapk inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional braf activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained erk inhibition maximizes responses of brafv600e thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0024","article-title":"Redifferentiation-facilitated radioiodine therapy in thyroid cancer","volume":"28","author":"Lamartina","year":"2021","journal-title":"Endocrine Related Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0632","article-title":"Redifferentiation of differentiated thyroid cancer: clinical insights from a narrative review of literature","volume":"33","author":"Van Nostrand","year":"2023","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B45","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"Ras proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocrine-related Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0583","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features accounts for more than half of \u201ccarcinomas\u201d harboring ras mutations","volume":"27","author":"Paulson","year":"2017","journal-title":"Thyroid"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.29935","article-title":"Papillary thyroid cancer: genetic alterations and molecular biomarker investigations","volume":"16","author":"Abdullah","year":"2019","journal-title":"Int J Med Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ng.115.","article-title":"Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon","volume":"40","author":"Haigis","year":"2018","journal-title":"Nature genetics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1111\/j.1755-3768.2014.4246.x","article-title":"Sf3b1 and eif1ax mutations in uveal melanoma: a protective factor, or not","volume":"92","author":"Kilic","year":"2015","journal-title":"Acta Ophthalmologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2478\/folmed-2018-0078","article-title":"Genetics of Thyroid Disorders","volume":"61","author":"Cort\u00e9s","year":"2019","journal-title":"Folia medica"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer: A J Am Cancer Soc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hed.22997","article-title":"Brafv600e mutation in fine-needle aspiration aspirates: association with poorer prognostic factors in larger papillary thyroid carcinomas","volume":"35","author":"Lee","year":"2013","journal-title":"Head Neck"},{"key":"B54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cncr.v110:1","article-title":"Clinicopathologic significance ofbraf v600e mutation in papillary carcinomas of the thyroid","volume":"110","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31826a9c71","article-title":"Braf mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis","volume":"91","author":"Tufano","year":"2012","journal-title":"Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/hed.21142","article-title":"Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in brafv600e mutation, clinicopathological features, and immunohistochemical findings","volume":"32","author":"Park","year":"2010","journal-title":"Head Neck"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011-0123","article-title":"Mutational patterns and novel mutations of the braf gene in a large cohort of Korean patients with papillary thyroid carcinoma","volume":"22","author":"Jung","year":"2012","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4389","article-title":"High-sensitivity braf mutation analysis: braf v600e is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas","volume":"99","author":"de Biase","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2390","article-title":"Association of high iodine intake with the t1799a braf mutation in papillary thyroid cancer","author":"Guan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-016-2027-5","article-title":"In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation","volume":"469","author":"Nasirden","year":"2016","journal-title":"Virchows Archiv: an Int J Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04541-w","article-title":"Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study","volume":"149","author":"Ding","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13044-024-00209-4","article-title":"Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements","volume":"17","author":"Uno","year":"2024","journal-title":"Thyroid Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00721-1","article-title":"Papillary thyroid carcinoma: correlation between molecular and clinical features","volume":"28","author":"Wang","year":"2024","journal-title":"Mol diagnosis Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03911-3","article-title":"A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma","volume":"86","author":"Haghzad","year":"2024","journal-title":"Endocrine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"133944","DOI":"10.1016\/j.ijbiomac.2024.133944","article-title":"Cd147 protein molecule expression and chromosomal instability in the pathogenesis and prognosis of thyroid cancer","volume":"276","author":"Zhou","year":"2024","journal-title":"Int J Biol Macromolecules"},{"key":"B67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.23750\/abm.v89i9-S.7960","article-title":"Microsatellite instability in colorectal cancer","volume":"89","author":"De\u2019 Angelis","year":"2018","journal-title":"Acta bio-medica: Atenei Parmensis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1238051","article-title":"CD147: an integral and potential molecule to abrogate hallmarks of cancer","volume":"13","author":"Nyalali","year":"2023","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.198","article-title":"Determinants and clinical implications of chromosomal instability in cancer. Nature reviews","volume":"15","author":"Sansregret","year":"2018","journal-title":"Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4251\/wjgo.v14.i3.690","article-title":"Cost-effective low-coverage whole-genome sequencing assay for the risk stratification of gastric cancer","volume":"14","author":"Ye","year":"2022","journal-title":"World J gastrointestinal Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1359231","article-title":"Detection of chromosomal instability using ultrasensitive chromosomal aneuploidy detection in the diagnosis of precancerous lesions of gastric cancer","volume":"15","author":"Qian","year":"2024","journal-title":"Front Genet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg4521","article-title":"Oncogene-like addiction to aneuploidy in human cancers","volume":"381","author":"Girish","year":"2023","journal-title":"Sci (New York N.Y.)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-013-1523-0","article-title":"Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma","volume":"464","author":"Behnes","year":"2014","journal-title":"Virchows Archiv: an Int J Pathol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/ijmm.2019.4408","article-title":"Apoptotic SKOV3 cells stimulate M0 macrophages to differentiate into M2 macrophages and promote the proliferation and migration of ovarian cancer cells by activating the ERK signaling pathway","volume":"45","author":"Zhang","year":"2020","journal-title":"Int J Mol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front Immunology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"108646","DOI":"10.1016\/j.intimp.2022.108646","article-title":"Radiation therapy regulates TCF-1 to maintain CD8+T cell stemness and promotes anti-tumor immunotherapy","volume":"107","author":"Wang","year":"2022","journal-title":"Int immunopharmacology,107"},{"key":"B79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12105-019-01101-6","article-title":"Tumor infiltrating lymphocytes and CD8+\u2009T cell subsets as prognostic markers in patients with surgically treated laryngeal squamous cell carcinoma","volume":"14","author":"Chatzopoulos","year":"2020","journal-title":"Head Neck Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"18125","DOI":"10.1038\/s41598-024-69187-9","article-title":"The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001455R","article-title":"Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5-CXCR2 signaling","volume":"35","author":"Lee","year":"2021","journal-title":"FASEB journal: Off Publ Fed Am Societies Exp Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S216829","article-title":"Demethylation and overexpression of CSF2 are involved in immune response, chemotherapy resistance, and poor prognosis in colorectal cancer","volume":"12","author":"Xu","year":"2019","journal-title":"OncoTargets Therapy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3892\/ijo.2015.3041","article-title":"CXCL5\/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K\/AKT-induced upregulation of MMP2\/MMP9","volume":"47","author":"Gao","year":"2015","journal-title":"Int J Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2642-1","article-title":"The effect of CCL19\/CCR7 on the proliferation and migration of cell in prostate cancer","volume":"36","author":"Peng","year":"2015","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biol Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.3390\/ijms23169006","article-title":"Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer","volume":"23","author":"Shields","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1021\/nn5004277","article-title":"Emerging role of nanomaterials in circulating tumor cell isolation and analysis","volume":"8","author":"Yoon","year":"2014","journal-title":"ACS nano"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.37349\/etat","article-title":"Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer","volume":"4","author":"Caputo","year":"2023","journal-title":"Explor targeted anti-tumor Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"New Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/cancers15041284","article-title":"The position of circulating tumor DNA in the clinical management of colorectal cancer","volume":"15","author":"de Abreu","year":"2023","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","first-page":"13767","DOI":"10.3390\/ijms241813767","article-title":"CTC, ctDNA, and exosome in thyroid cancers: A review","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21178","article-title":"Detect able BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas","volume":"32","author":"Chuang","year":"2010","journal-title":"Head Neck"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v111.6","article-title":"Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis","volume":"111","author":"Lan","year":"2020","journal-title":"Cancer Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.03.026","article-title":"Epigenetic signature associated with thyroid cancer progression and metastasis","volume":"83","author":"Zhang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S231361","article-title":"Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas","volume":"13","author":"Jiang","year":"2020","journal-title":"OncoTargets Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/cancers13081946","article-title":"The role of macrophages in cancer development and therapy","volume":"13","author":"Cendrowicz","year":"2021","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:25:50Z","timestamp":1747805150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":100,"alternative-id":["10.3389\/fonc.2025.1598934"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1598934","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1598934"}}